Century Therapeutics, Inc. Share Price & Technical Analysis
IPSC · $2.26 (-0.44%)
Healthcare / Biotechnology
$2.26
-0.44%
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the devel…
Price chart
Seasonality
May has 1 positive and 1 negative years (last 5 years shown)
0% return in May, 1% avg return in past 3 year May month.
111% return in 2026, -9% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 90% | 21% | 0% | 0% | 0% | – | – | – | – | – | – | – | 111% |
| 25 | -20% | -12% | -29% | 0% | 0% | 20% | -17% | 0% | 0% | 20% | -17% | 100% | 46% |
| 24 | 30% | -12% | 14% | -31% | 0% | -17% | -12% | -18% | 0% | -39% | 42% | -41% | -84% |
| 23 | -10% | -2% | -22% | -11% | 3% | 0% | -6% | -17% | -20% | -25% | -12% | 136% | 13% |
| 22 | -18% | 11% | -9% | -5% | -27% | -3% | 26% | 0% | -5% | 4% | -1% | -51% | -78% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$414.81M
P/E ratio
—
52W high
$3.04
52W low
$0.43
Volume
5,31,889
Beta
1.56
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Century Therapeutics, Inc. share price today?
- Century Therapeutics, Inc. (IPSC) last traded around $2.26 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IPSC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IPSC. Download the app for real-time alerts.
- How can I analyze Century Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.